Anika Therapeutics turns to Q2 FY26 net income of 3.31 million; revenue rises 16% to 32.61 million
ANIK•Channel revenue and Hyalofast update
- OEM Channel revenue increased 14% to $18.71 million.
- Commercial Channel revenue climbed 17% to $13.91 million.
Hyalofast remains under FDA PMA review, with the company responding to a deficiency letter received in January 2026.
Q2 revenue and profitability improve
Anika Therapeutics reported Q2 revenue of $32.61 million, up 16% year over year, as gross margin widened 14 percentage points to 65%.
Net income turned to $3.31 million, or $0.24 per diluted share, from a loss a year earlier.
Adjusted EBITDA (non-GAAP) rose to $7.06 million from a loss a year earlier.
